ClinicalTrials.gg
CompletedNCT04270747Updated Sep 10, 2025Results posted

A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]

A Phase 3 interventional study of ABP 938 and Aflibercept in Neovascular (Wet) Age-related Macular Degeneration (AMD), sponsored by Amgen. Completed at 118 sites in 18 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
576
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
5th of 66
576 · median 55
Started
2020
with 1 other
Phase 3
18 of 66
1 open now
Registered
46th of 66
by date
Lead sponsor
2 of 66
Amgen

Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 5th largest by enrollment, is one of 2 that started in 2020, is one of 18 in phase 3, and was the 46th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of ABP 938 versus Aflibercept (Eylea®) in the treatment of neovascular age-related macular degeneration. Subjects will be randomized in a masked 1:1 ratio to receive 2 mg (0.05 mL) of either ABP 938 (Treatment Group A) or aflibercept (Treatment Group B) administered by intravitreal (IVT) injection.

Read the detailed description

Approximately 566 subjects will be randomized in approximately 126 global sites.

This study consists of a screening period of up to 4 weeks, after which subjects will receive investigational product for 48 weeks, followed by a safety follow-up period to week 52, for a total study duration of up to 56 weeks.

Subjects will be randomized in a masked 1:1 ratio to receive 2 mg (0.05 mL) of either ABP 938 (Treatment Group A) or aflibercept (Treatment Group B) administered by IVT injection.

At week 8, subjects will be assessed for the primary endpoint. The primary endpoint is the change in Best Corrected Visual Acuity (BCVA) as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score from baseline to week 8, in order to assess the efficacy of ABP 938 compared to aflibercept.

Subjects will then be re-randomized at week 16 in a masked fashion such that:

  • Subjects initially randomized to ABP 938 (Treatment Group A) will continue to receive ABP 938 by IVT injection every 8 weeks from week 16 until week 48
  • Subjects initially randomized to aflibercept (Treatment Group B) will be re-randomized in a 1:1 ratio to either continue on aflibercept (Treatment Group B1) or transition to ABP 938 (Treatment Group B2) by IVT injection every 8 weeks from week 16 until week 48
03

Conditions studied

  • Neovascular (Wet) Age-related Macular Degeneration (AMD)
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects or their legally authorized representative must sign an Institutional Review Board/Independent Ethics Committee approved form before any study-specific procedures
  • Men or women ≥ 50 years old
  • Subjects must be diagnosed with neovascular (wet) AMD in the study eye
  • Active treatment naïve subfoveal CNV lesions secondary to neovascular (wet) AMD including juxtafoveal lesions that affect the fovea as confirmed with SD OCT, FA and/or Fundus Photography (FP) in the study eye
  • BCVA between 73 and 34 letters, inclusive, in the study eye using ETDRS testing
  • Presence of intra and/or subretinal fluid as identified by SD-OCT attributable to active CNV in the study eye
  • Central retinal thickness of > 270µm in the study eye as measured by the machine, calculated average thickness in the central 1 mm subfield (CST) by SD-OCT at screening

Exclusion criteria

Exclusion Criteria:

Subjects are excluded if they meet any of the following criteria in the study eye:

  • Total lesion size > 12 disc areas (30.5 mm\^2, including blood, scars, and neovascularization) in the study eye
  • Active CNV area (classic plus occult components) that is \< 50% of the total lesion area in the study eye
  • Scar, fibrosis, or atrophy involving the center of the fovea in the study eye
  • Presence of retinal pigment epithelium tears or rips involving the macula in the study eye
  • History of any vitreous hemorrhage within 4 weeks before randomization in the study eye
  • Presence of other causes of CNV, including pathologic myopia (spherical equivalent of 8 diopters or more negative or axial length of 25 mm or more), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis in the study eye
  • Prior vitrectomy or laser surgery of the macula (including photodynamic therapy or focal laser photocoagulation) in the study eye
  • History of retinal detachment in the study eye
  • Any history of macular hole of stage 2 and above in the study eye
  • Any macular pathology that might limit vision i.e., Vitreomacular traction or significant epiretinal membrane in the study eye
  • Any intraocular or periocular surgery within 3 months before randomization on the study eye, except lid surgery, which may not have taken place within 4 weeks before randomization, as long as it is unlikely to interfere with the injection
  • Prior trabeculectomy or other filtration surgery in the study eye
  • Uncontrolled glaucoma (defined as intraocular pressure ≥ 25 mmHg despite treatment with antiglaucoma medication) in the study eye
  • Aphakia or pseudophakia with complete absence of posterior capsule (unless it occurred as a result of a yttrium aluminum garnet [YAG] posterior capsulotomy) in the study eye
  • Previous therapeutic radiation in the region of the study eye
  • History of corneal transplant or corneal dystrophy in the study eye
  • Significant media opacities, including cataract, which might interfere with visual acuity or assessment of safety, in the study eye
  • Any concurrent intraocular condition other than neovascular (wet) AMD in the study eye that, in the opinion of the investigator, requires planned medical or surgical intervention during the study or increases the risk to the subject beyond what is expected from standard procedures of intraocular injection, or which otherwise may interfere with the injection procedure or with evaluation of efficacy or safety

Subjects are excluded if they meet any of the following criteria in either eye:

  • History or clinical evidence of uveitis, diabetic retinopathy, diabetic macular edema, or any other vascular disease affecting the retina, other than neovascular (wet) AMD
  • Active intraocular inflammation or active or suspected ocular or periocular infection, within 2 weeks before randomization
  • Active scleritis or episcleritis or presence of scleromalacia

Other Medical Conditions

  • Active extraocular infection or history of extraocular infections as follows: A. any active infection for which systemic anti-infectives were used within 4 weeks before randomization B. recurrent or chronic infections or other active infection that, in the opinion of the investigator, might cause this study to be detrimental to the subject
  • Acute coronary event or stroke within 3 months before randomization
  • Uncontrolled, systemic disease such as diabetes mellitus, hypertension, cardiovascular disease including moderate to severe heart failure ( class III/IV), renal disease, or liver disease
  • within 5 years EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, in situ cervical cancer, OR in situ breast ductal carcinoma

Washouts and Nonpermitted Treatments

  • Any prior ocular or systemic treatment, including another product or surgery for neovascular (wet) AMD (including anti vascular endothelial growth factor [VEGF] therapy) in the study eye, except dietary supplements or vitamins
  • Any ocular or systemic treatment including another investigational product or surgery for neovascular (wet) AMD (including anti VEGF therapy) in the fellow eye, within 30 days before randomization, except dietary supplements or vitamins
  • Prior systemic anti-VEGF treatment as follows:
  • Investigational or approved anti-VEGF therapy systemically within 3 months before randomization
  • Aflibercept, ziv-aflibercept, or a biosimilar of aflibercept/ziv-aflibercept systemically at any time
  • Any IVT therapy, including adrenocorticotropic hormone, in the study or fellow eye, or intramuscular or intravenous within 4 weeks before randomization. The use of long-acting steroids, either systemically or intraocularly, in the 3 months before randomization
  • Currently receiving treatment with another investigational device or study drug, or less than 30 days or 5 half-lives (whichever is longer) since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded

General

  • For women: pregnant or breast feeding, or planning to become pregnant while enrolled in the study and for 3 months after the last dose of investigational product
  • Sexually active subjects and their partners who are of (ie, neither surgically sterile nor ) and not agreeing to use adequate (eg, true abstinence, sterilization, birth control pills, Depo Provera injections, contraceptive implants, or other effective methods) while on study and for 3 months after the last dose of study drug. Male subjects must agree not to donate sperm during study and for 3 months following treatment with test article or until the scheduled end of the study (whichever is longer)
  • Allergy or to investigational product, to any of the of ABP 938 or aflibercept, or to other study-related procedures/medications (eg, anesthesia, antiseptic, fluorescein dye)
  • History or evidence of any other clinically significant disorder, condition, or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion
  • Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (eg, Clinical Outcome Assessments) to the best of the subject and investigator's knowledge
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
576 participants (actual)

Study arms

  • Experimental
    ABP 938-Treatment Group A

    Subjects will receive 2 mg (0.05 mL) of ABP 938 by intravitreal (IVT) injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8) and every 8 weeks from week 16 until week 48.

    Drug: ABP 938

  • Active comparator
    Aflibercept-Treatment Group B1

    Subjects will receive 2 mg (0.05 mL) of aflibercept (Treatment Group B) by IVT injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8). Subjects will be re-randomized to receive aflibercept by IVT injection every 8 weeks from week 16 until week 48.

    Drug: Aflibercept

  • Active comparator
    ABP 938-Treatment group B2

    Subjects will receive 2 mg (0.05 mL) of aflibercept (Treatment Group B) by IVT injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8). Subjects will be re-randomized to receive ABP 938 by IVT injection every 8 weeks from week 16 until week 48

    Drug: ABP 938 · Drug: Aflibercept

Interventions

  • Subject will receive ABP 938 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks

  • Subject will receive aflibercept 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks

    Also known as: Eylea®

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in BCVA at Week 8

    BCVA score was assessed based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart by the study eye at 4 meters. ETDRS letters score could range from 0 to 100 letters at each assessment. A positive change from Baseline in ETDRS letter score indicated an improvement in visual acuity in the study eye. Change from Baseline calculated as observed post-baseline value - Baseline value.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Percentage of Participants Who Maintained Vision at Week 52

    A participant was classified as maintaining vision if he/she lost fewer than 15 letters in ETDRS letter score, assessed in the study eye, compared to Baseline.

    Time frame: Week 52

  2. Mean Change From Baseline in BCVA

    BCVA score was assessed based on the number of letters read correctly on the ETDRS chart by the study eye at 4 meters. ETDRS letters score could range from 0 to 100 letters at each assessment. A positive change from Baseline in ETDRS letter score indicated an improvement in visual acuity in the study eye. Change from Baseline calculated as observed post-baseline value - Baseline value.

    Time frame: Baseline and Weeks 4, 8, 16, 24, 32, 40, 48, and 52

  3. Percentage of Participants Who Gained at Least 10 Letters of Vision at Week 8

    Percentage of participants who gained at least 10 letters of vision was assessed based on the number of letters read correctly on the ETDRS chart by the study eye at 4 meters. ETDRS letters score could range from 0 to 100 letters at each assessment.

    Time frame: Week 8

  4. Percentage of Participants Who Gained at Least 15 Letters of Vision at Week 52

    Percentage of participants who gained at least 15 letters of vision was assessed based on the number of letters read correctly on the ETDRS chart by the study eye at 4 meters. ETDRS letters score could range from 0 to 100 letters at each assessment.

    Time frame: Week 52

  5. Mean Change From Baseline in Choroidal Neovascularization (CNV) Area Size

    CNV area size was measured by fluorescein angiography. Change from Baseline calculated as observed post-baseline value - Baseline value.

    Time frame: Baseline and Weeks 8, 16, 24, and 52

  6. Mean Change From Baseline in Central Subfield Thickness (CST)

    CST was defined as the average thickness in the ETDRS central 1 mm diameter subfield (the central subfield) and was measured by spectral domain optical coherence tomography. Change from Baseline calculated as observed post-baseline value - Baseline value.

    Time frame: Baseline and Weeks 4, 8, 16, 24, 32, 40, 48, and 52

  7. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical trial participant. TEAEs were defined as those AEs that begin or increase in severity or frequency at or after the time of first treatment to the End of Study visit. Events of interest (EOIs) pre-specified for this study included endophthalmitis, retinal detachment, increase in intraocular pressure, and thromboembolic events. Serious AEs were defined as any untoward medical occurrence that meets at least 1 of the following serious criteria: * Results in death * Life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Congenital anomaly/birth defect * Other medically important serious event.

    Time frame: Up to Week 52

  8. Number of Participants Developing Binding Antidrug Antibodies (ADAs)

    Number of participants with positive post-baseline ADA result through Week 16 and post Week 16 with negative or no result at Baseline is reported.

    Time frame: Baseline up to Week 52

07

Results

Posted Jan 5, 2024

Participant flow

This study was conducted at 102 centers in Canada, Czech Republic, Estonia, Germany, Hong Kong, Hungary, Israel, Italy, Japan, South Korea, Latvia, Lithuania, Poland, Slovakia, Spain, and the United States between 22 June 2020 and 30 January 2023.

Through Week 16
Participant flow — Through Week 16
MilestoneABP 938 / ABP 938Aflibercept / AfliberceptAflibercept / ABP 938
Started2882880
Completed2732700
Not completed15180
Withdrew: Adverse event120
Withdrew: Death020
Withdrew: Consent withdrawn330
Withdrew: Physician decision110
Withdrew: Lost to follow-up200
Withdrew: Protocol violation120
Withdrew: Protocol specified criteria670
Withdrew: Miscellaneous110
Post Week 16
Participant flow — Post Week 16
MilestoneABP 938 / ABP 938Aflibercept / AfliberceptAflibercept / ABP 938
Started273136134
Received treatment273136133
Completed251125123
Not completed221111
Withdrew: Adverse event751
Withdrew: Death202
Withdrew: Consent withdrawn436
Withdrew: Physician decision311
Withdrew: Lost to follow-up210
Withdrew: Requirement for alternative therapy100
Withdrew: Requirement for alternative dosing schedule210
Withdrew: Miscellaneous101

Outcome measures

PrimaryMean Change From Baseline in BCVA at Week 8

BCVA score was assessed based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart by the study eye at 4 meters. ETDRS letters score could range from 0 to 100 letters at each assessment. A positive change from Baseline in ETDRS letter score indicated an improvement in visual acuity in the study eye. Change from Baseline calculated as observed post-baseline value - Baseline value.

Time frame:
Baseline and Week 8
Reported as:
Mean · Letters
Mean Change From Baseline in BCVA at Week 8
LettersABP 938Aflibercept
Mean Change From Baseline in BCVA at Week 86.4 ± 8.186.5 ± 8.97
Statistical analysis
  • ABP 938 vs Aflibercept · Difference between means: 0.1 · 90% CI -1.1 to 1.3Estimated using analysis of covariance (ANCOVA) model adjusted for the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA as covariates.
SecondaryPercentage of Participants Who Maintained Vision at Week 52

A participant was classified as maintaining vision if he/she lost fewer than 15 letters in ETDRS letter score, assessed in the study eye, compared to Baseline.

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Maintained Vision at Week 52
Percentage of ParticipantsABP 938 / ABP 938Aflibercept / AfliberceptAflibercept / ABP 938
Percentage of Participants Who Maintained Vision at Week 5295.6 (93.1 to 98.2)97.6 (94.9 to 100.0)95.9 (92.5 to 99.4)
Statistical analysis
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Risk difference (rd): -2.1 · 90% CI -5.2 to 2.2Estimated using the stratified Newcombe confidence limits (with Mantel-Haenszel weights) adjusting for stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters).
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Risk difference (rd): -1.7 · 90% CI -6.2 to 2.8Estimated using the stratified Newcombe confidence limits (with Mantel-Haenszel weights) adjusting for stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters).
SecondaryMean Change From Baseline in BCVA

BCVA score was assessed based on the number of letters read correctly on the ETDRS chart by the study eye at 4 meters. ETDRS letters score could range from 0 to 100 letters at each assessment. A positive change from Baseline in ETDRS letter score indicated an improvement in visual acuity in the study eye. Change from Baseline calculated as observed post-baseline value - Baseline value.

Time frame:
Baseline and Weeks 4, 8, 16, 24, 32, 40, 48, and 52
Reported as:
Mean · Letters
Mean Change From Baseline in BCVA
LettersABP 938 / ABP 938Aflibercept / AfliberceptAflibercept / ABP 938
Week 45.0 ± 6.575.4 ± 8.353.8 ± 8.19
Week 86.5 ± 8.107.6 ± 9.305.6 ± 8.86
Week 166.8 ± 8.697.5 ± 9.317.1 ± 9.32
Week 247.2 ± 9.637.1 ± 9.307.0 ± 10.12
Week 327.1 ± 11.008.7 ± 9.216.6 ± 11.11
Week 407.3 ± 11.008.1 ± 11.007.9 ± 10.08
Week 487.2 ± 11.518.7 ± 10.848.1 ± 10.74
Week 527.6 ± 11.609.4 ± 10.188.0 ± 11.14
Statistical analysis
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: -0.1 · 90% CI -1.3 to 1.2Estimated using ANCOVA model adjusted for the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA as covariates.
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: -0.8 · 90% CI -2.3 to 0.7Estimated using ANCOVA model adjusted for the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA as covariates.
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: -0.3 · 90% CI -1.9 to 1.2Estimated using ANCOVA model adjusted for the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA as covariates.
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: 0.4 · 90% CI -1.3 to 2.1Estimated using ANCOVA model adjusted for the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA as covariates.
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: -1.3 · 90% CI -3.1 to 0.5Estimated using ANCOVA model adjusted for the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA as covariates.
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: -0.5 · 90% CI -2.3 to 1.4Estimated using ANCOVA model adjusted for the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA as covariates.
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: -1.2 · 90% CI -3.2 to 0.8Estimated using ANCOVA model adjusted for the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA as covariates.
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: -1.5 · 2% CI -3.4 to 0.5Estimated using ANCOVA model adjusted for the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: -1.5 · 90% CI -3.0 to 0.0Estimated using ANCOVA model adjusted for the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: -1.9 · 90% CI -3.6 to -0.2Estimated using ANCOVA model adjusted for the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: -0.3 · 90% CI -2.1 to 1.5Estimated using ANCOVA model adjusted for the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: 0.0 · 90% CI -1.9 to 2.0Estimated using ANCOVA model adjusted for the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: -1.9 · 90% CI -4.0 to 0.2Estimated using ANCOVA model adjusted for the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: 0.0 · 90% CI -2.2 to 2.2Estimated using ANCOVA model adjusted for the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: -0.6 · 90% CI -2.9 to 1.7Estimated using ANCOVA model adjusted for the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: -1.2 · 90% CI -3.5 to 1.1Estimated using ANCOVA model adjusted for the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA as covariates.
SecondaryPercentage of Participants Who Gained at Least 10 Letters of Vision at Week 8

Percentage of participants who gained at least 10 letters of vision was assessed based on the number of letters read correctly on the ETDRS chart by the study eye at 4 meters. ETDRS letters score could range from 0 to 100 letters at each assessment.

Time frame:
Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants Who Gained at Least 10 Letters of Vision at Week 8
Percentage of participantsABP 938Aflibercept
Percentage of Participants Who Gained at Least 10 Letters of Vision at Week 829.4 (24.1 to 34.7)32.7 (27.3 to 38.2)
Statistical analysis
  • ABP 938 vs Aflibercept · Risk difference (rd): -3.4 · 90% CI -9.8 to 3.1Estimated using the stratified Newcombe confidence limits (with Mantel-Haenszel weights) adjusting for stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters).
SecondaryPercentage of Participants Who Gained at Least 15 Letters of Vision at Week 52

Percentage of participants who gained at least 15 letters of vision was assessed based on the number of letters read correctly on the ETDRS chart by the study eye at 4 meters. ETDRS letters score could range from 0 to 100 letters at each assessment.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Gained at Least 15 Letters of Vision at Week 52
Percentage of participantsABP 938 / ABP 938Aflibercept / AfliberceptAflibercept / ABP 938
Percentage of Participants Who Gained at Least 15 Letters of Vision at Week 5224.3 (19.0 to 29.6)29.6 (21.6 to 37.6)24.4 (16.8 to 32.0)
Statistical analysis
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Risk difference (rd): -5.3 · 90% CI -13.6 to 2.5Estimated using the stratified Newcombe confidence limits (with Mantel-Haenszel weights) adjusting for stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters).
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Risk difference (rd): -5.2 · 90% CI -14.4 to 4.2Estimated using the stratified Newcombe confidence limits (with Mantel-Haenszel weights) adjusting for stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters).
SecondaryMean Change From Baseline in Choroidal Neovascularization (CNV) Area Size

CNV area size was measured by fluorescein angiography. Change from Baseline calculated as observed post-baseline value - Baseline value.

Time frame:
Baseline and Weeks 8, 16, 24, and 52
Reported as:
Mean · mm^2
Mean Change From Baseline in Choroidal Neovascularization (CNV) Area Size
mm^2ABP 938 / ABP 938Aflibercept / AfliberceptAflibercept / ABP 938
Week 8-4.962 ± 5.1604-5.479 ± 5.1023-5.169 ± 4.6943
Week 16-4.089 ± 5.3668-5.174 ± 5.2280-4.751 ± 4.8814
Week 24-4.323 ± 5.5972-5.308 ± 5.6238-5.121 ± 5.2776
Week 52-6.276 ± 6.2690-7.280 ± 5.8262-6.434 ± 5.2445
Statistical analysis
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: -0.048 · 90% CI -0.734 to 0.638Estimated using ANCOVA model with treatment, Baseline CNV measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: 0.431 · 90% CI -0.367 to 1.229Estimated using ANCOVA model with treatment, Baseline CNV measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: 0.197 · 90% CI -0.625 to 1.019Estimated using ANCOVA model with treatment, Baseline CNV measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: 0.156 · 2% CI -0.561 to 0.872Estimated using ANCOVA model with treatment, Baseline CNV measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: 0.105 · 90% CI -0.682 to 0.891Estimated using ANCOVA model with treatment, Baseline CNV measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: 0.245 · 90% CI -0.667 to 1.158Estimated using ANCOVA model with treatment, Baseline CNV measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: -0.116 · 90% CI -1.065 to 0.834Estimated using ANCOVA model with treatment, Baseline CNV measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: 0.647 · 90% CI -0.186 to 1.479Estimated using ANCOVA model with treatment, Baseline CNV measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
SecondaryMean Change From Baseline in Central Subfield Thickness (CST)

CST was defined as the average thickness in the ETDRS central 1 mm diameter subfield (the central subfield) and was measured by spectral domain optical coherence tomography. Change from Baseline calculated as observed post-baseline value - Baseline value.

Time frame:
Baseline and Weeks 4, 8, 16, 24, 32, 40, 48, and 52
Reported as:
Mean · μm
Mean Change From Baseline in Central Subfield Thickness (CST)
μmABP 938 / ABP 938Aflibercept / AfliberceptAflibercept / ABP 938
Week 4-136.5 ± 108.91-143.1 ± 107.32-149.7 ± 107.01
Week 8-145.9 ± 106.24-146.3 ± 110.39-167.4 ± 118.52
Week 16-125.2 ± 124.81-127.3 ± 103.35-143.2 ± 121.93
Week 24-130.8 ± 125.63-131.7 ± 102.98-151.2 ± 118.21
Week 32-133.2 ± 122.93-134.1 ± 116.02-154.8 ± 114.22
Week 40-132.3 ± 113.25-135.6 ± 119.07-155.7 ± 119.95
Week 48-132.3 ± 124.15-141.1 ± 112.29-157.8 ± 121.23
Week 52-157.1 ± 114.25-159.1 ± 108.82-177.4 ± 122.22
Statistical analysis
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: 6.2 · 90% CI -5.6 to 17.9Estimated using ANCOVA model with treatment, Baseline CST measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: 1.3 · 90% CI -11.0 to 13.5Estimated using ANCOVA model with treatment, Baseline CST measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: 1.9 · 90% CI -12.9 to 16.6Estimated using ANCOVA model with treatment, Baseline CST measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: 0.1 · 90% CI -14.1 to 14.4Estimated using ANCOVA model with treatment, Baseline CST measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: -1.2 · 90% CI -15.3 to 12.9Estimated using ANCOVA model with treatment, Baseline CST measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: 0.2 · 90% CI -13.7 to 14.1Estimated using ANCOVA model with treatment, Baseline CST measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: 7.0 · 90% CI -7.4 to 21.4Estimated using ANCOVA model with treatment, Baseline CST measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • ABP 938 / ABP 938 vs Aflibercept / Aflibercept · Difference between means: 1.6 · 2% CI -9.3 to 12.5Estimated using ANCOVA model with treatment, Baseline CST measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: 6.3 · 90% CI -7.4 to 20.0Estimated using ANCOVA model with treatment, Baseline CST measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: -5.1 · 90% CI -19.3 to 9.1Estimated using ANCOVA model with treatment, Baseline CST measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: -3.8 · 90% CI -20.9 to 13.3Estimated using ANCOVA model with treatment, Baseline CST measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: -6.0 · 90% CI -22.6 to 10.6Estimated using ANCOVA model with treatment, Baseline CST measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: -7.0 · 90% CI -23.3 to 9.3Estimated using ANCOVA model with treatment, Baseline CST measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: -6.5 · 90% CI -22.8 to 9.8Estimated using ANCOVA model with treatment, Baseline CST measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: -0.5 · 90% CI -17.3 to 16.2Estimated using ANCOVA model with treatment, Baseline CST measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
  • Aflibercept / Aflibercept vs Aflibercept / ABP 938 · Difference between means: 2.3 · 90% CI -10.5 to 15.0Estimated using ANCOVA model with treatment, Baseline CST measurement and the stratification factors geographic region (East Asia, Europe, North America) and Baseline BCVA (BCVA \< 64 letters, BCVA ≥ 64 letters) as covariates.
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a clinical trial participant. TEAEs were defined as those AEs that begin or increase in severity or frequency at or after the time of first treatment to the End of Study visit. Events of interest (EOIs) pre-specified for this study included endophthalmitis, retinal detachment, increase in intraocular pressure, and thromboembolic events. Serious AEs were defined as any untoward medical occurrence that meets at least 1 of the following serious criteria: * Results in death * Life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Congenital anomaly/birth defect * Other medically important serious event.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsThrough Week 16: ABP 938Through Week 16: AfliberceptPost Week 16: ABP 938 / ABP 938Post Week 16: Aflibercept / ABP 938Post Week 16: Aflibercept / Aflibercept
Any TEAEs1131071447672
Any EOIs63982
Any Serious TEAEs69221411
SecondaryNumber of Participants Developing Binding Antidrug Antibodies (ADAs)

Number of participants with positive post-baseline ADA result through Week 16 and post Week 16 with negative or no result at Baseline is reported.

Time frame:
Baseline up to Week 52
Reported as:
Count of participants · Participants
Number of Participants Developing Binding Antidrug Antibodies (ADAs)
ParticipantsThrough Week 16: ABP 938Through Week 16: AfliberceptPost Week 16: ABP 938 / ABP 938Post Week 16: Aflibercept / ABP 938Post Week 16: Aflibercept / Aflibercept
Number of Participants Developing Binding Antidrug Antibodies (ADAs)14430

Adverse events

Collected over Up to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Through Week 16: ABP 9380/288 (0%)6/288 (2.1%)18/288 (6.3%)
Through Week 16: Aflibercept2/288 (0.7%)9/288 (3.1%)15/288 (5.2%)
Post Week 16: ABP 938 / ABP 9382/273 (0.7%)22/273 (8.1%)20/273 (7.3%)
Post Week 16: Aflibercept / ABP 9382/133 (1.5%)14/133 (10.5%)17/133 (12.8%)
Post Week 16: Aflibercept / Aflibercept0/136 (0%)11/136 (8.1%)17/136 (12.5%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventThrough Week 16: ABP 938Through Week 16: AfliberceptPost Week 16: ABP 938 / ABP 938Post Week 16: Aflibercept / ABP 938Post Week 16: Aflibercept / Aflibercept
Cerebrovascular accidentNervous system disorders0/2880/2882/2733/1330/136
Femur fractureInjury, poisoning and procedural complications1/2880/2883/2730/1330/136
Acute myocardial infarctionCardiac disorders0/2880/2880/2731/1330/136
Cardiac failure congestiveCardiac disorders0/2880/2880/2731/1330/136
AppendicitisInfections and infestations0/2880/2880/2731/1330/136
PneumoniaInfections and infestations0/2881/2881/2731/1330/136
ContusionInjury, poisoning and procedural complications0/2880/2880/2731/1330/136
FallInjury, poisoning and procedural complications0/2880/2880/2731/1330/136
Rib fractureInjury, poisoning and procedural complications0/2880/2880/2731/1330/136
Heart rate decreasedInvestigations0/2880/2880/2731/1330/136
Most frequent other events
Most frequent other events
EventThrough Week 16: ABP 938Through Week 16: AfliberceptPost Week 16: ABP 938 / ABP 938Post Week 16: Aflibercept / ABP 938Post Week 16: Aflibercept / Aflibercept
Neovascular age-related macular degenerationEye disorders6/2884/28816/27310/13311/136
Conjunctival haemorrhageEye disorders12/28811/2884/2738/1338/136

Baseline characteristics

Full Analysis Set: Consisted of all randomized participants, with treatment as the randomized treatment regardless of actual treatment received. Participants were included in the treatment group in which they were initially randomized.

Age, Continuous
Age, Continuous(Years)ABP 938AfliberceptTotal
Mean76.0 ± 7.9376.0 ± 7.9576.0 ± 7.93
Sex: Female, Male
Sex: Female, Male(Participants)ABP 938AfliberceptTotal
Female151171322
Male137117254
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ABP 938AfliberceptTotal
Hispanic or Latino61319
Not Hispanic or Latino281275556
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ABP 938AfliberceptTotal
Asian363975
Black or African American112
Multiple101
White250248498
08

Study locations

118 sites
  • Associated Retina Consultants, Ltd. - Research
    Phoenix, Arizona 85020, United States
  • Retina Consultants of Orange County
    Fullerton, California 92835, United States
  • UCSD Shiley Eye Institute, Jacobs Retina Center
    La Jolla, California 92093, United States
  • Jules Stein Eye Institute, UCLA
    Los Angeles, California 90095-7000, United States
  • Southern California Desert Retina Consultants
    Palm Desert, California 92211, United States
  • Retina Consultants San Diego
    Poway, California 92064, United States
  • Retina Consultants of Southern California
    Redlands, California 92374, United States
  • Retinal Consultants Medical Group, Inc.
    Sacramento, California 95825, United States
  • Orange County Retina Medical Group
    Santa Ana, California 92705, United States
  • Miramar Eye Specialists
    Ventura, California 93003, United States
  • Colorado Retina Associates
    Lakewood, Colorado 80228, United States
  • Retina Group of New England
    Waterford, Connecticut 06385, United States
  • Florida Retina Consultants
    Lakeland, Florida 33805, United States
  • Medeye Associates
    Miami, Florida 33143, United States
  • Center for Retina and Macular Disease
    Winter Haven, Florida 33880, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • Georgia Retina, P.C.
    Marietta, Georgia 30060, United States
  • Retina Associates IL
    Elmhurst, Illinois 60126, United States
  • Sabates Eye Center
    Leawood, Kansas 66211, United States
  • Retina Associates New Orleans
    Metairie, Louisiana 70006, United States
  • The Retina Care Center
    Baltimore, Maryland 21209, United States
  • Specialty Eye Institute
    Jackson, Michigan 49202, United States
  • Retina Center
    Saint Louis Park, Minnesota 55416, United States
  • Retina Vitreous Surgeons of Central NY, PC
    Liverpool, New York 13088, United States
  • Macula Care
    New York, New York 10021, United States
  • Ophthalmic Consultants of the Capital Region - Ophthalmology
    Troy, New York 12180, United States
  • Charlotte Eye Ear Nose & Throat Associates, P.A.
    Charlotte, North Carolina 28210, United States
  • Sterling Research Group
    Cincinnati, Ohio 45219, United States
  • Eye Care Specialists
    Kingston, Pennsylvania 18704, United States
  • Charleston Neuroscience Institute
    Ladson, South Carolina 29456, United States
  • Black Hills Regional Eye Institute - Ophthalmology
    Rapid City, South Dakota 57701, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Retina Consultants of Texas Research Centers
    Bellaire, Texas 77401, United States
  • Texas Retina Associates
    Dallas, Texas 75231, United States
  • Texas Retina Associates
    Fort Worth, Texas 76012, United States
  • Texas Retina Associates
    Fort Worth, Texas 76014, United States
  • Ophthalmology Associates
    Fort Worth, Texas 76102, United States
  • Premiere Retina Specialists
    Midland, Texas 79706, United States
  • Retina Associates of South Texas, P.A.
    San Antonio, Texas 78240-1375, United States
  • Retina Consultants of Houston
    The Woodlands, Texas 77384, United States
  • Strategic Clinical Research
    Willow Park, Texas 76087, United States
  • University of Ottawa Eye Institute
    Ottawa, Ontario K1H 8L6, Canada
  • Clinique d'ophtalmologie des laurentides
    Boisbriand, Quebec J7H 0E8, Canada
  • Ocni klinika Pardubice
    Pardubice, 530 02, Czechia
  • FN Kralovske Vinohrady
    Prague, 100 34, Czechia
  • Vseobecna fakultni nemocnice v Praze
    Prague, 128 08, Czechia
  • Axon Clinical, s.r.o.
    Prague, 150 00, Czechia
  • Krajska zdravotni, a.s. Masarykova nemocnice v Usti n/ Labem
    Ústí nad Labem, Ústí Nad Labem 401 13, Czechia
  • East Tallinn Central Hospital - Eye Clinic
    Tallinn, Harju 10138, Estonia
  • Eye Clinic of Dr. Krista Turman
    Tallinn, Harju 11314, Estonia
  • Silmalaser OÜ
    Tallinn, Harju 11412, Estonia
  • Eye Clinic of Tartu University Hospital
    Tartu, Tartu 50406, Estonia
  • University Medical Center Freiburg
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Klinikum Darmstadt
    Darmstadt, Hesse 64283, Germany
  • Universitätsmedizin Göttingen
    Göttingen, Lower Saxony 37075, Germany
  • St. Franziskus Hospital Münster
    Münster, North Rhine-Westphalia 48145, Germany
  • Universitätsmedizin Mainz
    Mainz, Rhineland-Palatinate 55131, Germany
  • Charité Universitätsmedizin Berlin KöR
    Berlin, 12203, Germany
  • University Hospital Of Leipzig
    Leipzig, 04103, Germany
  • The University of Hong Kong - Department of Ophthalmology
    Aberdeen, 000000, Hong Kong
  • Prince of Wales Hospital - Department of Ophthalmology and Visual Sciences
    Shatin, New Territories, 000000, Hong Kong
  • Ganglion Orvosi Központ
    Pécs, Baranya 7621, Hungary
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpo
    Szeged, Csongrád megye 6720, Hungary
  • Debreceni Egyetem Klinikai Központ
    Debrecen, Hajdú-Bihar 4032, Hungary
  • Péterfy Kórház-Rendelintézet és Manninger Jen Országos Traumatológiai Intézet - Szemészeti Osztály
    Budapest, 1076, Hungary
  • Bajcsy-Zsilinszky Kórház és Rendelintézet
    Budapest, 1106, Hungary
  • Budapest Retina Intezet
    Budapest, 1133, Hungary
  • MH Egészségügyi Központ
    Budapest, H-1062, Hungary
  • Semmelweis Egyetem
    Budapest, H-1083, Hungary
  • Meir Medical Center
    Kfar Saba, Central District 4428164, Israel
  • Soroka University Medical Center
    Beersheba, Southern District 8410101, Israel
  • Bnai Zion Medical Center
    Haifa, Southern District 3104802, Israel
  • Kaplan Medical Center
    Rehovot, 7610001, Israel
  • Assaf Harofeh Medical Center
    Ẕerifin, 7030000, Israel
  • Fondazione PTV Policlinico Tor Vergata, UNIT Patologie Retiniche
    Rome, Lazio 00133, Italy
  • UOC Oculistica Fondazione PU A.Gemelli IRCCS Un.Cattolica del Sacro Cuore
    Rome, Lazio 00168, Italy
  • Università degli Studi di Perugia, Ospedale Santa Maria della Misericordia, Clinica Oculistica
    Perugia, Umbria 06129, Italy
  • UO Oftalmologia Ciardella Pol. S.Orsola Malpighi AOU di Bologna
    Bologna, 40138, Italy
  • "Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, UO Oculistica Dipartimento di Chirurgia"
    Milan, 20122, Italy
  • Nagoya University Hospital
    Nagoya, Aiti 466-8560, Japan
  • Nagoya City University Hospital - Ophthalmology
    Nagoya, Aiti 467-8602, Japan
  • Nagoya University Hospital
    Nagoya, Aiti, Japan
  • Asahikawa Medical University Hospital
    Asahikawa, Hokkaidô 078-8510, Japan
  • Fukushima Medical University Hospital - Ophthalmology
    Fukushima, Hukusima 960-1295, Japan
  • Kagoshima University Hospital - Ophthalmology
    Kagoshima, Kagoshima-ken 890-8520, Japan
  • Mie University Hospital
    Tsu, Mie-ken 514-8507, Japan
  • Nihon University Hospital - Ophthalmology
    Tokyo, Tôkyô 101-8309, Japan
  • University of Yamanashi Hospital
    Chūō, Yamanashi 409-3898, Japan
  • Akita University Hospital - Ophthalmology
    Akita, 010-8543, Japan
  • Nagasaki University Hospital - Ophthalmology
    Nagasaki, 852-8501, Japan
  • Kansai Medical University Hospital - Ophthalmology
    Hirakata, Ôsaka 573-1191, Japan
  • P.Stradina Clinical University Hospital
    Riga, Rga 1002, Latvia
  • Signes Ozolinas Doctor Praxis in Ophthalmology
    Jelgava, LV- 3001, Latvia
  • Klaipedos Universitetine ligoniene
    Klaipėda, Klaipdos Apskritis LT-92288, Lithuania
  • Vilniaus Universiteto Ligonines Santariskiu Klinikos (VULSK)
    Vilnius, Vilnius County 8661, Lithuania
  • Asociación para Evitar la Ceguera en México I.A.P.
    México DF, Mexico City 04030, Mexico
  • Centro Medico Zambrano Hellion
    Monterrey, Nuevo León 64710, Mexico
  • Centro de Retina Medica y Quirurgica S.C.
    Zapopan, 45116, Mexico
  • Szpital Sw. Wojciecha
    Poznan, Greater Poland Voivodeship 61-144, Poland
  • Profesorskie Centrum Okulistyki OKULISTYKA OPTIMUM
    Gdansk, Pomeranian Voivodeship 80-809, Poland

Showing the first 100 of 118 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Chow V, Zhou M, Mytych DT, Colbert A, Miller MJ, Wala I, Sabet A, Radziszewski W. Pharmacokinetic, Safety, and Immunogenicity Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab-Atto. Pharmacol Res Perspect. 2026 Apr;14(2):e70236. doi: 10.1002/prp2.70236. PubMed 41857488 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Jul 2022, 24 months.

Results were first posted in Jan 2024, 1 year 5 months after primary completion. A results delay was requested in May 2023.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 24 months is close to that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2020
First posted
Feb 17, 2020
StartActual
Jun 22, 2020
Primary completionActual
Jul 18, 2022
CompletionActual
Jan 30, 2023
Results delay requested
May 16, 2023
Results first posted
Jan 5, 2024
Last update
Sep 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04270747
Lead sponsor
Amgen
Collaborators
Parexel
Responsible party
Sponsor
First posted
Feb 17, 2020
Start date
Jun 22, 2020
Primary completion
Jul 18, 2022
Completion
Jan 30, 2023
Results posted
Jan 5, 2024
Last update
Sep 10, 2025

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion